Five upcoming psychedelic clinical trials you don’t want to miss

Psychedelics are being tested as novel treatments in 403 trials.

From psilocybin to MDMA, these compounds – often in combination with therapy – are showing promise for PTSD, depression, and other mental health issues.

With sub-par treatments currently available, psychedelics promise an alternative way of helping those in need.

Here are 5 upcoming clinical trials that we’re looking forward to going ahead.

1. A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders (MED1)

Organised by MAPS, this Phase II study will explore the safety and feasibility of MDMA-assisted therapy (MDMA-AT) in the treatment of 18 participants with eating disorders.

The study will recruit 12 individuals with anorexia nervosa & 6 with binge eating disorder.

The study will follow a protocol similar to that used in the MAPS MDMA-AT trial for PTSD which is now in Phase III.

2. An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder

The PsykForsk research team at Østfold hospital in Norway will conduct the world’s first trial using investigating MDMA-AT in people with major depressive disorder (MDD).

The study will use the Montgomery and Asberg Depression Rating Scale (MADRS) to determine the effectiveness of MDMA-AT in treating MDD.

PsyckForsk researcher, Tor-Morten Kvam, is interested to see what will surface as a result of the therapy and “what kinds of attachment issues or relational issues could contribute to someone’s depression.”

Check out our recent conversation with Tor-Morten here.

3. Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Tryp Therapeutics is planning a Phase IIa open-label study to determine the safety and feasibility of a single dose of their psilocybin formulation, TRP-8802, in people with binge eating disorder.

10 participants will be given a single dose of TRP-8802 and psychotherapy in a program that will last for 12 weeks.

4. Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Revive Therapeutics & the University of Wisconsin-Madison will investigate the safety and feasibility of two oral doses of psilocybin when combined with behavioural support for methamphetamine use disorder (MUD).

This is the first-time psychedelics will be used and tested in people with MUD.

5. Effects of Psilocybin in Post-Treatment Lyme Disease

Researchers at Johns Hopkins University will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).

This pilot study will involve 20 participants and psychological support will be provided.

These are just five upcoming studies that have piqued our curiosity here at Blossom.

You can find all trials in our free trials database.